Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biofarma Positioning For Growth in Turkish Market

This article was originally published in PharmAsia News

Executive Summary

Biofarma, one of the dynamic actors in the challenging Turkish pharmaceutical market, put up a strong performance in 2012–13 and its owners are now looking to benefit. So far, information on a likely share sale by one or both of the firm’s two investors has not been released, but Biofarma is looking forward to new opportunities and as sales and marketing director Gurhan Kaba told PharmAsia News in an exclusive interview, “Biofarma is a platform ready to grow.”

You may also be interested in...

GSK Reportedly Bidding For Turkish Biofarma, Local Manufacturing Key To Market Registration

GlaxoSmithKline PLC is rumored to be among three final bidders for Turkish generic drug maker Biofarma Pharmaceutical Industry Co. Inc. MNCs in Turkey are stepping up plans to establish a local manufacturing presence in Turkey to respond to continued price pressure, according to analysts

Turkey’s $2.6Bn Hospital Medtech Debts Create Problems On Top Of COVID-19

Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.

COVID-19 Pushes Ongoing Concerns of Turkish Medtech Industry Down The Agenda

The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts